InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q3 Results, Conference Call

February 6, 2024 13:19:53

Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it will host a conference call and webcast to report results for its fiscal year 2024 third quarter ended Dec. 31, 2023, and provide a corporate update. The call will begin at 2:00 p.m. Pacific Time on Tuesday, Feb. 13, 2024. Interested parties should dial 1-877-407-9716 (U.S. toll-free) or 1-201-493-6779 (international) and enter conference ID 13743176 to join the call and visit to register for and join the webcast. Participants are asked to access the webcast site 10 minutes before the start of the call. A telephone playback of the call will be available as detailed in the announcement.

To view the full press release, visit

About VistaGen Therapeutics Inc.

Vistagen is a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders. Five of Vistagen’s six clinical-stage product candidates belong to a new class of drugs known as pherines, which have the potential to rapidly deliver meaningful efficacy with a differentiated safety profile. Pherines are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuits in the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen’s sixth clinical-stage product candidate, AV-101, is an investigational oral drug candidate with the potential to inhibit, but not block, NMDA receptor activity. Vistagen is passionate about transforming what is possible in the treatment of anxiety, depression and other neuroscience disorders. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at 

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office

InvestorWire is powered by IBN